Literature DB >> 32520639

Response to Lim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19".

Vikram Sengupta1,2, Sascha Sengupta2,3, Angel Lazo4, Kevin C Hicok5, Timothy Moseley5.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32520639      PMCID： PMC7374618          DOI： 10.1089/scd.2020.0095

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN： 1547-3287            Impact factor:   3.272


× No keyword cloud information.
  3 in total

1.  Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al.

Authors:  Sai Kiang Lim; Bernd Giebel; Daniel J Weiss; Kenneth W Witwer; Eva Rohde
Journal:  Stem Cells Dev       Date:  2020-06-10       Impact factor: 3.272

2.  Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.

Authors:  Jennifer G Wilson; Kathleen D Liu; Hanjing Zhuo; Lizette Caballero; Melanie McMillan; Xiaohui Fang; Katherine Cosgrove; Rosemary Vojnik; Carolyn S Calfee; Jae-Woo Lee; Angela J Rogers; Joseph Levitt; Jeanine Wiener-Kronish; Ednan K Bajwa; Andrew Leavitt; David McKenna; B Taylor Thompson; Michael A Matthay
Journal:  Lancet Respir Med       Date:  2014-12-17       Impact factor: 30.700

3.  Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.

Authors:  Vikram Sengupta; Sascha Sengupta; Angel Lazo; Peter Woods; Anna Nolan; Nicholas Bremer
Journal:  Stem Cells Dev       Date:  2020-05-12       Impact factor: 3.272
  3 in total
  3 in total

Review 1.  Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects.

Authors:  Mai Abdelgawad; Nourhan Saied Bakry; Ahmed A Farghali; Ahmed Abdel-Latif; Ahmed Lotfy
Journal:  Stem Cell Res Ther       Date:  2021-08-21       Impact factor: 6.832

Review 2.  COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?

Authors:  Philip W Askenase
Journal:  J Extracell Vesicles       Date:  2020-11-14

Review 3.  Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID-19 and similar lung diseases.

Authors:  Behnaz Banimohamad-Shotorbani; Hekmat Farajpour; Farshid Sefat; Shiva Ahdi Khosroshahi; Hajar Shafaei; Saeed Heidari Keshel
Journal:  Biotechnol Bioeng       Date:  2021-03-27       Impact factor: 4.395
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.